Core Viewpoint - The ongoing trademark dispute between Wanglaoji and Jia Duo Bao highlights the complexities of intellectual property rights as Chinese brands expand internationally, with both companies asserting their claims over the "Wanglaoji" trademark in various global markets [1][3][6]. Group 1: Trademark Dispute Developments - On September 30, Jia Duo Bao announced victories in multiple lawsuits in Canada and the EU, claiming to protect its overseas trademark rights for "Wanglaoji," asserting ownership since the early 2000s and registration in over 60 countries [1]. - Wanglaoji quickly countered, accusing Jia Duo Bao of misleading the public and revealing that it has initiated trademark protection actions in 21 countries, with some jurisdictions already ruling in favor of Wanglaoji [2]. - The trademark conflict stems from over two decades of partnership and subsequent legal battles, with a recent ruling ordering Jia Duo Bao to pay Wanglaoji 317 million yuan for trademark infringement [3]. Group 2: Market Context and Growth Challenges - Despite dominating the domestic herbal tea market, both companies face stagnation as new beverage categories divert consumer interest, prompting a focus on international expansion [4]. - Wanglaoji has seen its overseas market grow 6.5 times over the past decade, with a compound annual growth rate exceeding 25%, and has registered its trademarks in over 100 countries [4]. - Both companies are establishing local production bases to enhance their market presence, with Wanglaoji partnering with local firms to build an 800 million can annual capacity in Malaysia [4]. Group 3: Intellectual Property Challenges - The trademark battle reflects broader challenges faced by Chinese companies in protecting their intellectual property abroad, with over 2,000 instances of trademark registration disputes reported since the 1980s, leading to significant asset losses [6][7]. - The regional nature of trademark laws complicates enforcement, as different jurisdictions have varying principles regarding trademark rights, impacting both companies' strategies [6][7]. - The difficulty in proving malicious registration adds to the complexity, as companies must gather evidence across borders, which can be costly and time-consuming [7]. Group 4: Strategic Recommendations - Experts suggest that traditional brands must integrate intellectual property into their core strategies, emphasizing the importance of comprehensive planning and proactive trademark registration [2][8]. - Companies are advised to enhance their brand narratives and cultural heritage to secure broader trademark protections and avoid potential conflicts in international markets [8]. - The case serves as a cautionary tale for Chinese enterprises aiming for global expansion, underscoring the necessity of clarifying trademark rights before entering new markets [9].

Core Insights - Guangdong Pharmaceutical Yunshan Molecular Technology (Guangzhou) Co., Ltd. has been established with a registered capital of 500 million yuan, focusing on medical research and development, investment activities, and sales of Class II medical devices [1][2]. Company Information - The legal representative of the company is Kong Jian, and it is wholly owned by Baiyunshan (600332) [1]. - The company is registered in Huangpu District, Guangzhou, Guangdong Province, with a business scope that includes medical research and experimental development, technology services, and sales of medical devices [2]. Registration Details - The company was registered with a unified social credit code of 91440112MAEWX6L36M and has a business duration until September 30, 2025, with no fixed term thereafter [2]. - The registration address is located at Yichuang Street, Knowledge City, Huangpu District, Guangzhou [2].

Core Viewpoint - The Chinese medicine sector shows resilience with the Chinese Medicine ETF (560080) rising by 0.28% despite market fluctuations, indicating strong investor interest and a net inflow of over 220 million yuan in the past 10 days [1][3]. Market Performance - The Chinese Medicine ETF (560080) has maintained a premium, closing with a premium rate of 0.14%, and has seen a total trading volume exceeding 1 billion yuan [1]. - Major stocks within the ETF, such as Dong'e Ejiao and Yunnan Baiyao, have shown positive performance, with Dong'e Ejiao increasing by over 1% [3][4]. Index Performance - The Chinese medicine index has experienced a negative return of -2.86% year-to-date, with a decline of 8.13% projected for 2024 [4]. - The index has shown a pattern of alternating performance, with three consecutive years of gains from 2019 to 2021, followed by three years of declines from 2016 to 2018 [4]. Valuation Metrics - The TTM price-to-earnings ratio for the Chinese Medicine ETF (560080) stands at 24.86, placing it at the 20.6% percentile of the past decade, suggesting a favorable valuation [6]. Financing and Investment Trends - Leveraged funds are increasingly utilizing the ETF for exposure to the higher-value Chinese medicine consumer sector, with the latest financing balance exceeding 91 million yuan, maintaining historical highs [7]. - The overall sentiment in the Chinese medicine sector is expected to improve, driven by stable market demand and accelerated innovation [9]. Future Outlook - The Chinese medicine sector is anticipated to benefit from innovation and transformation, with a focus on new product development and cost reductions in raw materials [9][10]. - The sector is positioned to leverage its advantages in preventive healthcare and as a complementary treatment alongside Western medicine [10]. Corporate Governance and Incentives - Recent corporate governance improvements and incentive plans in state-owned enterprises are expected to drive growth in the Chinese medicine sector, with companies like Huaren Sanjiu and Jiangzhong Pharmaceutical implementing effective incentive programs [11][12]. Dividend Yield - Several Chinese medicine companies are projected to have dividend yields exceeding 3% in 2024, with state-owned enterprises leading in this regard, indicating strong cash flow and shareholder returns [13][14].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會會議召開日期 董事會 中國廣州，2025年10月14日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2025年10月28日（星期 二）舉行董事會會議，藉以審議及批准本公司及其附屬公司截至2025年9月30日止九個月未經審計財 務業績及處理其他事項（如有）。 廣州白雲山醫藥集團股份有限公司 ...

格隆汇10月14日丨白云山(00874.HK)公布，谨定于2025年10月28日(星期二)举行董事会会议，藉以审议 及批准公司及其附属公司截至2025年9月30日止九个月未经审计财务业绩及处理其他事项(如有)。 ...

格隆汇10月14日丨白云山(00874.HK)公布，谨定于2025年10月28日(星期二)举行董事会会议，藉以审议 及批准公司及其附属公司截至2025年9月30日止九个月未经审计财务业绩及处理其他事项(如有)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 董事會會議召開日期 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）茲通告謹定於2025年10月28日（星期 二）舉行董事會會議，藉以審議及批准本公司及其附屬公司截至2025年9月30日止九個月未經審計財 務業績及處理其他事項（如有）。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年10月14日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 ...

Core Viewpoint - The trademark dispute between Jia Duo Bao and Wang Lao Ji has intensified, particularly focusing on overseas trademark rights, as both companies seek to expand in international markets amid slowing domestic growth in the herbal tea sector [1][3][4]. Trademark Dispute Background - The conflict stems from a historical agreement where Li Yimin, former general manager of Guangzhou Pharmaceutical Group, facilitated the transfer of the "Wang Lao Ji" trademark to Jia Duo Bao's parent company, Hongdao Group, in exchange for bribes totaling HKD 3 million [1][11][15]. - Following the exposure of Li Yimin's bribery case, Guangzhou Pharmaceutical Group reassessed the licensing agreements, claiming the trademark was undervalued, with usage fees at only 0.03% of sales compared to the industry norm of 5%-30% [1][16][17]. Recent Developments - On September 29, Jia Duo Bao announced victories in multiple lawsuits in Canada and the EU, asserting its rights to the "Wang Lao Ji" trademark in over 60 countries through its subsidiary, Multi Access Limited [4][20]. - Conversely, Wang Lao Ji's parent company, Baiyunshan, issued a statement disputing Jia Duo Bao's claims, asserting that the trademark ownership is clear and legally documented [5][4]. Market Context - The herbal tea industry in China is experiencing a slowdown, with market growth rates declining significantly from 16.7% in 2012 to a mere 6.8% projected over the next five years [20][19]. - In contrast, the global plant beverage market is booming, with a compound annual growth rate of nearly 10% from 2019 to 2024, particularly in emerging markets like Southeast Asia [22][26]. Financial Performance - Baiyunshan reported a 12.7% decline in revenue from its health segment, which primarily includes Wang Lao Ji, with total revenue around CNY 9.7 billion for 2024 [21]. - In the first half of 2025, Wang Lao Ji's health segment showed signs of recovery, with a revenue increase of 8.38% to CNY 6.5 billion, and a net profit rise of 15.87% [24]. Strategic Moves - Wang Lao Ji is actively pursuing international expansion, launching the new overseas brand "WALOVI" and registering it in over 100 countries [5][22]. - The ongoing trademark battle is crucial for Jia Duo Bao, as securing overseas rights could enhance its market position and attract potential investors amid plans for a Hong Kong IPO [26].

Core Viewpoint - The ongoing trademark dispute between Wanglaoji and JDB (Jiangsu Dahe Beverage) has escalated, focusing on overseas trademark rights, with both companies asserting their claims in various international markets [2][4]. Group 1: Trademark Dispute Background - The trademark conflict between Wanglaoji and JDB has been ongoing for over a decade, involving issues of trademark licensing, commercial packaging, and advertising slogans [2][3]. - Wanglaoji's brand has a history dating back to the Qing Dynasty, and it became a national beverage during its operation under JDB [3]. - The initial trademark licensing agreement between Guangzhou Pharmaceutical Group and JDB was signed in the 1990s, with subsequent contracts leading to disputes over their validity due to alleged bribery [3][4]. Group 2: Recent Developments - JDB claims to have successfully defended its overseas trademark rights in multiple lawsuits, asserting ownership of the Wanglaoji brand in over 60 countries [2][5]. - Wanglaoji has countered these claims, accusing JDB of malicious trademark registration and has initiated legal actions in 21 countries, with some rulings already in its favor [6][5]. - The legal status of JDB's overseas trademark registrations varies by country, with some jurisdictions recognizing its legitimacy while others do not [6]. Group 3: Market Expansion Strategies - Both companies are aggressively pursuing international market expansion, with Wanglaoji launching a new brand name "WALOVI" to cater to global consumers [7][8]. - Wanglaoji's overseas market has seen a 6.5-fold growth over the past decade, with a compound annual growth rate exceeding 25% [7]. - JDB's international strategy appears more subdued, yet it continues to expand its marketing channels and product reach globally [8]. Group 4: Industry Trends - The global plant-based beverage market is experiencing significant growth, with a compound annual growth rate of nearly 10% from 2019 to 2024 [7]. - The competition in the herbal tea segment is intensifying, with both companies needing to adapt to changing consumer preferences and market dynamics [9]. - Analysts suggest that the trademark dispute is a reflection of the broader challenges faced by Chinese companies in international markets, emphasizing the importance of trademark rights in global expansion efforts [9].

Core Viewpoint - The dispute over the "Wang Lao Ji" trademark between Jia Duo Bao Group and Wang Lao Ji has escalated, with both parties claiming ownership and legitimacy of their respective trademarks in various jurisdictions [1][3][8]. Group 1: Trademark Ownership Claims - Jia Duo Bao Group asserts that it legally acquired the "Wang Lao Ji" trademark in the early 2000s and has registered it in over 60 countries and regions [1][3][5]. - Wang Lao Ji claims that the trademark ownership belongs to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, and they have legal documents to support their position [8]. - Both companies cite different court rulings to validate their claims, with Jia Duo Bao mentioning victories in Canadian and EU courts regarding their trademark registrations [8]. Group 2: Legal Actions and Responses - Wang Lao Ji has initiated legal challenges against Jia Duo Bao's trademark registrations in 21 countries, with 10 jurisdictions already ruling in favor of Wang Lao Ji by revoking Jia Duo Bao's trademark registrations [8]. - Jia Duo Bao emphasizes its commitment to protecting its brand and will take all necessary legal actions against any infringement or market disruption [5][6]. - The trademark registration strategies differ, with Jia Duo Bao using "WANG LAO JI" and "WONG LO KAT," while Wang Lao Ji has registered "WALOVI," although both parties agree on the Chinese name "王老吉" [8].